HiFiBiO Therapeutics concludes first cohort of Covid-19 antibody study
HiFiBiO Therapeutics has successfully completed the first cohort of the Phase I trial (NCT04590430) of SARS-CoV-2 neutralising antibody, HFB30132A, to…
Latest News
-
14 hours
-
16 hours
-
16 hours
-
1 day
-
14 hours
-
16 hours
-
16 hours
-
1 day
Novartis’ iptacopan reduces proteinuria in rare renal disease trial
Novartis has announced that interim analysis results from the Phase II trial of iptacopan (LNP023) showed the oral therapy significantly…
Latest News
View More
Lilly and Boehringer report positive outcomes in heart failure trial
Eli Lilly and Boehringer Ingelheim have reported that new exploratory sub-analysis data from the EMPEROR-Reduced Phase III trial showed Jardiance (empagliflozin) helped reduce the risk…
Dicerna’s nedosiran achieves urinary oxalate normalisation in PH trial
Dicerna Pharmaceuticals has reported positive interim data from its ongoing PHYOX3 trial of investigational drug candidate, nedosiran, for the treatment of three known types of primary…
Goldfinch Bio reports positive data from GFB-887 trial
Goldfinch Bio has reported positive results from its Phase I clinical trial of GFB-887, a highly potent and selective inhibitor…
Moderna completes enrolment for mRNA-1273 trial against Covid-19
Moderna has completed the enrolment of participants for the Phase III COVE study of its vaccine candidate, mRNA-1273, against Covid-19.…
Daiichi Sankyo begins oncology therapy trial for metastatic tumours
Daiichi Sankyo has dosed the first patient in a first-in-human global Phase I trial to evaluate a Glycoprotein-A Repetitions Predominant…
Participant in AstraZeneca’s Brazilian Covid-19 trial dies
Brazilian health agency Anvisa has announced that a volunteer in the Brazilian trial of AstraZeneca and Oxford University’s investigational Covid-19…
Latest Content
View More
Pfizer’s 20vPnC boosts immune response in pneumococcal disease trial
Pfizer has reported full analysis data from one of its Phase III trials of its 20-valent pneumococcal conjugate vaccine (20vPnC)…
Appili Therapeutics doses first patients in Covid-19 clinical trial
Canada-based Appili Therapeutics has enrolled and dosed the first cluster of participants in its Phase II CONTROL COVID-19 clinical trial…
WAKIX (pitolisant) for the Treatment of Cataplexy with Narcolepsy
WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS)…
Real Time Cargo Intelligence to Increase Distribution Quality and Security
Smooth visibility from the place of production to the ultimate destination must be the new standard for vaccine delivery. The…
SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody. It is indicated for the treatment…
SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment of diseases with a high…